Real Patient Tirzepatide Reviews: Weight Loss Results and Side Effects
What real patients report about tirzepatide for weight loss. We summarize clinical trial outcomes and common themes from public reviews without invented quotes.
Tirzepatide is the first dual GIP/GLP-1 receptor agonist approved for chronic weight management. The drug produced weight loss percentages that had never been recorded in any pharmaceutical obesity trial before it. Online reviews now number in the thousands across Reddit, patient forums and telehealth review pages. Most of those reviews lack context. This page pairs the actual clinical trial data with the patterns we see across public patient feedback so you can separate verified outcomes from noise.
Clinical Trial Results That Patients Reference
When people post about tirzepatide results online, they often cite numbers without naming the source. Nearly every figure traces back to the SURMOUNT clinical trial program. Four major trials tested tirzepatide for weight loss in different populations. We focus on SURMOUNT-1 and SURMOUNT-2 here because they generate the most discussion.
SURMOUNT-1 Weight Loss by Dose
SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus at least one weight-related comorbidity. None had type 2 diabetes. Participants received weekly subcutaneous injections of tirzepatide at 5 mg, 10 mg or 15 mg, or placebo, for 72 weeks. The primary endpoint was percent change in body weight from baseline (PMID 35658024).
Results were dose-dependent. The 5 mg group lost 15.0% of body weight. The 10 mg group lost 19.5%. The 15 mg group lost 20.9%. Placebo lost 3.1%. At the highest dose, 57% of participants achieved 20% or greater weight loss. No prior obesity drug had produced numbers close to these in a phase 3 trial.
These figures represent the treatment-estimand analysis, meaning they reflect what happened to people who stayed on the assigned dose for the full 72 weeks. The numbers appear in almost every tirzepatide review thread, though few posters specify which estimand they are quoting.
SURMOUNT-2 Results in Type 2 Diabetes Patients
SURMOUNT-2 tested tirzepatide specifically in adults with type 2 diabetes and a BMI of 27 or higher. This matters because patients with type 2 diabetes typically lose less weight on GLP-1 receptor agonists than patients without the condition. The trial ran for 72 weeks and included 938 participants (PMID 37385275).
Even in this harder-to-treat population, tirzepatide produced substantial results. Participants also saw improvements in glycemic control, which is expected given that tirzepatide was originally developed and approved as a diabetes medication under the brand name Mounjaro. The dual benefit of weight reduction and blood sugar improvement drives many of the positive reviews from patients who have both conditions. You can read more about tirzepatide's week-by-week progression data on our before-and-after page.
Common Themes in Public Tirzepatide Reviews
We analyzed several hundred public posts across Reddit, patient review aggregators and telehealth forums to identify recurring themes. What follows is a summary of patterns rather than a cherry-picked collection of individual anecdotes. No specific patient stories are quoted because we cannot verify them.
Appetite Suppression
The single most common topic in positive reviews is reduced appetite. Patients describe it in different terms. Some say food simply stops occupying their thoughts. Others report that portions they once considered normal now feel excessive. A smaller group describes a change in food preferences, particularly a reduced interest in highly processed or sugar-dense foods.
This aligns with what the drug is designed to do. GLP-1 and GIP receptor activation slows gastric emptying and modulates appetite signaling in the hypothalamus. The subjective experience of "food noise" disappearing is the human translation of a well-characterized pharmacological mechanism. It is the most frequently cited reason people say they plan to continue treatment.
Nausea in the First Weeks
Nausea is the most common negative theme. In SURMOUNT-1, nausea occurred in up to 33% of tirzepatide-treated participants according to the Zepbound FDA label. Online reviews confirm this pattern. Most patients who mention nausea say it peaked during dose escalation and improved after two to four weeks at a stable dose.
A subset of reviews describe nausea severe enough to delay dose increases. This is consistent with clinical practice, where providers sometimes hold patients at a lower dose for an extra four weeks before titrating up. The dose-escalation schedule exists specifically to manage gastrointestinal tolerability.
Sustained Weight Loss After Month Three
Many reviewers note that steady, noticeable weight loss became apparent around weeks 10 through 14. The trial data supports this. Weight loss curves in SURMOUNT-1 show a steep decline in the first 20 weeks, with the rate slowing gradually through week 72 but never fully plateauing at the higher doses. Patients who stick with treatment beyond the initial adjustment period tend to report satisfaction with the trajectory. Those who discontinue early often cite side effects or cost.
Side Effects Patients Mention Most
The Zepbound label lists gastrointestinal events as the most frequent adverse reactions. Trial frequencies and the general tone of patient reports are compared below.
| Side Effect | Trial Frequency (up to) | What Patients Typically Report |
|---|---|---|
| Nausea | 33% | Worst during first 2-4 weeks and dose increases; often resolves |
| Diarrhea | 25% | Intermittent, usually mild; some link it to fatty meals |
| Vomiting | 13% | Less common than nausea alone; more frequent at higher doses |
| Constipation | Reported | Some patients describe alternating diarrhea and constipation |
| Injection site reactions | Reported | Mild redness or itching; rarely cited as a reason to stop |
| Fatigue | Reported | Some patients mention low energy during caloric deficit |
The Zepbound label also carries a boxed warning for thyroid C-cell tumors based on animal data, a contraindication in patients with MEN2 syndrome, and warnings for pancreatitis and gallbladder events. These serious risks rarely appear in casual online reviews but are covered in our tirzepatide safety and access guide.
Weight Loss Timeline from Trial Data
The chart below shows the approximate trajectory of weight loss across the 72-week SURMOUNT-1 trial. Weight loss was rapid in the first 20 weeks across all doses and continued at a slower rate through the remainder of the study. The placebo arm lost a small amount of weight, likely reflecting the lifestyle counseling all participants received.
Patients who expect linear weight loss week after week will not find it. The curve flattens as the body adapts. This flattening is normal and does not indicate treatment failure. It simply reflects the physics of a smaller body requiring fewer calories. The SURMOUNT-5 trial later showed that tirzepatide produced 20.2% weight loss at 72 weeks compared to 13.7% for semaglutide (PMID 40353578), which helps contextualize these results against the other major GLP-1 option.
What the Reviews Do Not Tell You
Survivorship Bias in Online Reviews
People who get great results are more likely to post about them. People who quit after six weeks because of nausea or cost are less likely to write a detailed review. This creates a skewed sample. The trial dropout rate provides a better picture. In SURMOUNT-1, roughly 14% to 17% of participants in the tirzepatide groups discontinued treatment before week 72, with adverse events being one of the documented reasons. Online review platforms do not capture these discontinuations at the same rate.
Missing Long-Term Maintenance Data
SURMOUNT-4 tested what happens when tirzepatide is withdrawn after 36 weeks of treatment. Participants who had lost an average of 20.9% of body weight were randomized to continue tirzepatide or switch to placebo. Those who stopped regained approximately 14% of their body weight over the following 52 weeks, while those who continued lost an additional 5.5% (PMID 38078870). Among those who stayed on the drug, 89.5% maintained at least 80% of their initial weight loss.
FAQ - Tirzepatide Weight Loss Reviews
How much weight do most people lose on tirzepatide?
In SURMOUNT-1, average weight loss ranged from 15.0% at the 5 mg dose to 20.9% at 15 mg over 72 weeks. Individual results vary. Some participants lost more than 25% of their body weight while others lost less than 10%. The 57% of participants achieving 20% or greater loss at the highest dose means a substantial minority did not reach that threshold.
Are online tirzepatide reviews reliable?
They reflect real subjective experiences but are subject to survivorship bias. People who respond well and stay on treatment are overrepresented. Trial data gives a more balanced view because it includes everyone who enrolled, including those who dropped out or had poor responses.
What is the most common complaint in tirzepatide reviews?
Nausea during the first weeks and during dose escalation. Up to 33% of trial participants experienced nausea. Most reviews indicate it decreases significantly after the body adjusts to each dose level. Cost is the second most common complaint, particularly for patients without insurance coverage for the branded product.
Does weight loss continue after the first few months?
Yes. SURMOUNT-1 data shows weight loss continued through week 72 at all doses, though the rate of loss slowed after approximately week 20. The curve does not plateau completely at the 10 mg and 15 mg doses, suggesting ongoing benefit with continued treatment. Stopping the medication leads to partial weight regain based on SURMOUNT-4 results.
Compare the current picks
Prices, sizes and ratings side by side, updated when the merchant pages change.
See providers